EDGE in Canada 

The clinical trials department of Juravinski Cancer Centre (JCC) of Hamilton Health Sciences adopted EDGE in 2011 as the first Canadian Pilot site, where they developed a close unique working relationship with us, the EDGE team. The success of using EDGE within the JCC led to many enquiries from other cancer research institutes and EDGE was soon selected by Canadian Cancer Clinical Trial’s Network (3CTN) as the preferred clinical trial management system for their network sites across Canada. Launched in June 2013, 3CTN set up EDGE centrally and initiated a pilot at the Ottawa Hospital Cancer Centre and British Columbia Cancer Agency (BCCA) sites. Since this, EDGE has been implemented across a number of network sites in great success and is expanding to more Canadian cancer centres, helping to improve the management of cancer clinical trials across the country.

The Alberta Clinical Research Consortium (ACRC) joined the EDGE community in January 2016 and launched an EDGE pilot for provincial research administration in March 2016.  The ACRC aims to provide EDGE to support clinical health research in all disease contexts, across Alberta with the goal of improving:  the quality of clinical health research management, understanding and uptake of best practice, the efficiency of the set-up of studies, and to enable the seamless exchange of information across organisations. ACRC, with EDGE as an enabling platform, continues to engage, support, and streamline processes with the research community.

The most recent Canadian organisation to join the EDGE system is the University of Saskatchewan located in Saskatoon, within the Saskatchewan province. The Clinical Trial Support Unit are currently piloting the system where they are working closely with the other Canadian groups in sharing ideas and best practises.

Click here to read some Canadian case studies

The potential value of EDGE for our province is huge. EDGE can do so much, from capabilities of tracking metrics on individual trials to creating tailored reports for our different stakeholders such as our funders, investigators, foundations and the public.
— Dr Bernie Eigl, Provincial Medical Director, British Columbia Cancer Agency